Sequent Scientific Limited (SEQUENT.BO)
INR 136.85
(3.52%)
INR 136.85
(3.52%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.87 Billion INR | 9.94% |
| 2022 | 4.43 Billion INR | 21.57% |
| 2021 | 3.64 Billion INR | 31.74% |
| 2020 | 2.76 Billion INR | -31.46% |
| 2019 | 4.04 Billion INR | 22.06% |
| 2018 | 3.31 Billion INR | 6.5% |
| 2017 | 3.1 Billion INR | -25.41% |
| 2016 | 4.16 Billion INR | 33.48% |
| 2015 | 3.12 Billion INR | -33.59% |
| 2014 | 4.7 Billion INR | 12.46% |
| 2013 | 4.18 Billion INR | 34.32% |
| 2012 | 3.11 Billion INR | 15.82% |
| 2011 | 2.68 Billion INR | 170.95% |
| 2010 | 991.92 Million INR | -43.36% |
| 2009 | 1.75 Billion INR | 80.54% |
| 2008 | 969.93 Million INR | 284.79% |
| 2007 | 252.06 Million INR | 477.67% |
| 2006 | 43.63 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 4.61 Billion INR | 0.0% |
| 2023 Q4 | 4.87 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 4.87 Billion INR | 9.94% |
| 2022 FY | 4.43 Billion INR | 21.57% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 4.27 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 4.43 Billion INR | 0.0% |
| 2021 Q2 | 3.08 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 3.64 Billion INR | 31.74% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 3.64 Billion INR | 0.0% |
| 2020 Q4 | 2.76 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 2.76 Billion INR | -31.46% |
| 2020 Q2 | 2.6 Billion INR | 0.0% |
| 2019 FY | 4.04 Billion INR | 22.06% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 4.04 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 3.13 Billion INR | 0.0% |
| 2018 Q4 | 3.31 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 3.31 Billion INR | 6.5% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q2 | 2.66 Billion INR | 0.0% |
| 2017 Q2 | 3.78 Billion INR | 0.0% |
| 2017 FY | 3.1 Billion INR | -25.41% |
| 2017 Q4 | 3.1 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 4.16 Billion INR | 33.48% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 3.98 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 4.16 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 3.12 Billion INR | 0.0% |
| 2015 Q2 | 2.66 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 3.12 Billion INR | -33.59% |
| 2014 FY | 4.7 Billion INR | 12.46% |
| 2014 Q2 | 3.51 Billion INR | 0.0% |
| 2014 Q4 | 4.7 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 FY | 4.18 Billion INR | 34.32% |
| 2013 Q4 | 4.18 Billion INR | 0.0% |
| 2012 Q2 | 1.94 Billion INR | 0.0% |
| 2012 Q4 | 3.11 Billion INR | 0.0% |
| 2012 FY | 3.11 Billion INR | 15.82% |
| 2011 FY | 2.68 Billion INR | 170.95% |
| 2010 FY | 991.92 Million INR | -43.36% |
| 2009 FY | 1.75 Billion INR | 80.54% |
| 2008 FY | 969.93 Million INR | 284.79% |
| 2007 FY | 252.06 Million INR | 477.67% |
| 2006 FY | 43.63 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 85.103% |
| NATCO Pharma Limited | 3.71 Billion INR | -31.383% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -650.338% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -572.804% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 352.8 Million INR | -1282.35% |
| Alkem Laboratories Limited | 14.18 Billion INR | 65.617% |
| Alpa Laboratories Limited | 52.46 Million INR | -9195.588% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 4.963% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -10506.172% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 92.664% |
| Bajaj HealthCare Limited | 3.32 Billion INR | -46.532% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -388.474% |
| Brooks Laboratories Limited | 56.41 Million INR | -8544.127% |
| Divi's Laboratories Limited | 30 Million INR | -16156.433% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 75.64% |
| Eris Lifesciences Limited | 27.81 Billion INR | 82.465% |
| FDC Limited | 205.18 Million INR | -2276.845% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 60.38% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -2744.023% |
| Granules India Limited | 13.15 Billion INR | 62.915% |
| Gufic Biosciences Limited | 3.32 Billion INR | -46.491% |
| Hester Biosciences Limited | 2.44 Billion INR | -99.565% |
| Indoco Remedies Limited | 6.71 Billion INR | 27.422% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -2834.092% |
| Ipca Laboratories Limited | 14.38 Billion INR | 66.094% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -5354.569% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -152.13% |
| Lasa Supergenerics Limited | 220.76 Million INR | -2109.135% |
| Laurus Labs Limited | 25.77 Billion INR | 81.078% |
| Lupin Limited | 29.21 Billion INR | 83.308% |
| Mankind Pharma Limited | 2.07 Billion INR | -135.404% |
| Medicamen Biotech Limited | 308.17 Million INR | -1482.535% |
| Medico Remedies Limited | 80.5 Million INR | -5957.997% |
| Megasoft Limited | 1.47 Billion INR | -231.658% |
| Piramal Pharma Limited | 47.1 Billion INR | 89.646% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Sigachi Industries Limited | 1.43 Billion INR | -240.921% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -697.536% |
| Unichem Laboratories Limited | 2.47 Billion INR | -97.036% |
| Wanbury Limited | 1.16 Billion INR | -318.676% |
| Windlas Biotech Limited | 36.41 Million INR | -13294.48% |
| ZIM Laboratories Limited | 1.08 Billion INR | -348.147% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 39.357% |
| Procter & Gamble Health Limited | 95.6 Million INR | -5001.391% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -28118.076% |
| Bal Pharma Limited | 1.39 Billion INR | -249.229% |
| Strides Pharma Science Limited | 25.16 Billion INR | 80.623% |
| Venus Remedies Limited | 413.3 Million INR | -1079.998% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | -70.97% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 23.263% |
| Shilpa Medicare Limited | 9.37 Billion INR | 47.973% |
| Aarti Drugs Limited | 5.64 Billion INR | 13.571% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -1388.684% |
| Suven Life Sciences Limited | 7.09 Million INR | -68618.191% |
| Ind-Swift Limited | 10.13 Billion INR | 51.904% |
| Valiant Laboratories Limited | 767.08 Million INR | -535.775% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | -29.135% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 51.785% |
| Themis Medicare Limited | 957.92 Million INR | -409.116% |
| Hikal Limited | 8.17 Billion INR | 40.349% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 87.874% |
| Novartis India Limited | 69.7 Million INR | -6897.03% |
| Wockhardt Limited | 23.56 Billion INR | 79.3% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 86.69% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -111017.111% |
| Neuland Laboratories Limited | 953.89 Million INR | -411.264% |
| Morepen Laboratories Limited | 289.99 Million INR | -1581.746% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -1441.065% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -395.157% |